Plum Bio terminates acquisition of Ipsin stake

On the evening of August 12,, Meihua Bio issued an anti-monopoly review announcement from the Ministry of Commerce:5XQMeihua Bio on matters related to the issuance of shares to purchase assets through the Ministry of Commerce's anti-monopoly review, it is proposed to issue shares to nine enterprises such as Tie Xiaorong and Ningxia Yipin Biotech Co., Ltdand pay 70 million yuan in cash to purchase 100% interest in Ningxia Yipin Biotech Co., LtdThe matter has been considered and approved by the 11th meeting of the 7th Board of Directors of the Company and the first interim general meeting of shareholders in 20155XQ
Today received the "Notice of Review Decision" issued by the Antimonopoly Bureau of the Ministry of Commerce of the People's Republic of China (Commercial Anti-Trump Review Letter No60), in accordance with the relevant provisions of the Anti-monopoly Law of the People's Republic of China, after examination, the acquisition of 100% equity of The company's Ibin Biological case is not prohibited, from now on, the concentration can be implementedThe case involves matters other than the centralized anti-monopoly examination of the operators and shall be handled in accordance with relevant laws5XQ
Then Meihua issued a further notice, suspension of trading, the proposed termination of the acquisition of Ispin made the following announcement:5XQdue to the restructuring of the proposed acquisition of assets have occurred affecting the transaction subject matters, the company comprehensive consideration of the various risk factors of the transaction, from the protection of the interests of all shareholders and maintain market stability, to decide to terminate the issue of shares and cash purchase assets and supporting the collection of fundsAs the Ministry of Commerce has issued relevant approval documents on this transaction, in order to avoid misleading the vast number of investors, ensure fair information disclosure, safeguard the interests of investors, avoid abnormal fluctuations in the stock price, the company's shares have been suspended since August 13, 2015 5XQ
　　The Company undertakes: The Company will conduct active communication and consultation with the intermediary and relevant parties as soon as possible to terminate this reorganization, and shall convene the Board of Directors to comply with the relevant procedures and make a timely announcement within 5 working days (including August 13, 2015) from the date of suspension of the stock 5XQ on the evening of August 12, Meihua Bio issued the Ministry of Commerce anti-monopoly review announcement: 5XQ Meihua Bio on the issue of shares to purchase assets through the Ministry of Commerce anti-monopoly review of matters, to issue shares to Iron Xiaorong and Ningxia Yipin Biotech Co., Ltd and other 9 enterprises and pay cash 70,000 yuan to purchase Ningxia Yipin Biotech Co., Ltd (hereinafter referred to as Yipin Biotech) 100% interest The matter has been considered and approved by the 11th meeting of the 7th Board of Directors of the Company and the first interim general meeting of shareholders in 2015 5XQ
　　Today received the "Notice of Review Decision" issued by the Antimonopoly Bureau of the Ministry of Commerce of the People's Republic of China (Commercial Anti-Trump Review Letter No 60), in accordance with the relevant provisions of the Anti-monopoly Law of the People's Republic of China, after examination, the acquisition of 100% equity of The company's Ibin Biological case is not prohibited, from now on, the concentration can be implemented The case involves matters other than the centralized anti-monopoly examination of the operators and shall be handled in accordance with relevant laws 5XQ
　　Then Meihua issued a further notice, suspension of trading, the proposed termination of the acquisition of Ispin made the following announcement: 5XQ due to the restructuring of the proposed acquisition of assets have occurred affecting the transaction subject matters, the company comprehensive consideration of the various risk factors of the transaction, from the protection of the interests of all shareholders and maintain market stability, to decide to terminate the issue of shares and cash purchase assets and supporting the collection of funds As the Ministry of Commerce has issued relevant approval documents on this transaction, in order to avoid misleading the vast number of investors, ensure fair information disclosure, safeguard the interests of investors, avoid abnormal fluctuations in the stock price, the company's shares have been suspended since August 13, 2015 5XQ
　　The Company undertakes: The Company will conduct active communication and consultation with the intermediary and relevant parties as soon as possible to terminate this reorganization, and shall convene the Board of Directors to comply with the relevant procedures and make a timely announcement within 5 working days (including August 13, 2015) from the date of suspension of the stock 5XQ
Share it on feed